1-Cyclopropyl-2,2-dimethylpropan-1-ol | 24382-76-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-Cyclopropyl-2,2-dimethylpropan-1-ol
• CAS: 24382-76-1
• 化学式: C₈H₁₆O
• 分子量: 128.214
• InChiKey: GRXCSPHKDYTYMJ-UHFFFAOYSA-N

物化性质

• 沸点：
  156.1±8.0 °C(Predicted)
• 密度：
  0.943±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-Cyclopropyl-2,2-dimethylpropan-1-ol 在 溴 、 三苯基膦 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 0.5h， 生成 (1-溴-2,2-二甲基丙基)环丙烷
  参考文献：
  名称：

  哌啶与1-溴-1-环丙基烷烃的均烯丙基取代反应

  摘要：

  当含溴碳被充分地空间位阻时，哌啶与1-溴-1-环丙基烷烃的反应提供了均一的取代产物的优异产率。

  DOI：

  10.1016/s0040-4039(00)94033-4
• 作为产物：
  描述：

  cyclopropyl tert-butyl ketone 在 lithium aluminium tetrahydride 作用下， 以 乙醚 为溶剂， 以69%的产率得到1-Cyclopropyl-2,2-dimethylpropan-1-ol
  参考文献：
  名称：

  Regioselective route to sterically hindered cyclopropylcarbinyl halides

  摘要：

  DOI：

  10.1021/jo00177a008

文献信息

• Fused Heterocyclic Compounds as Ion Channel Modulators
  申请人：Kobayashi Tetsuya

  公开号：US20120010192A1

  公开（公告）日：2012-01-12

  The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein R 1 , R 2 , R 3 , R 4 , and R 5 are as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.

  本公开涉及一类是钠通道抑制剂的化合物，以及它们在治疗各种疾病状态中的应用，包括心血管疾病和糖尿病。在特定实施例中，该类化合物的结构由式I给出：其中R1、R2、R3、R4和R5如本文所述，以及制备和使用该类化合物的方法，以及含有这些化合物的药物组合物。
• FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS
  申请人：Corkey Britton

  公开号：US20110021521A1

  公开（公告）日：2011-01-27

  The present invention relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein W 1 , W 2 , W 3 , R 1 , Q, X 1 , X 2 and X 3 are as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.

  本发明涉及一类钠通道抑制剂化合物，以及它们在治疗各种疾病状态中的应用，包括心血管疾病和糖尿病。具体实施例中，该化合物的结构由下式给出：其中W1、W2、W3、R1、Q、X1、X2和X3如本文所述，以及制备和使用该化合物的方法，以及含有该化合物的药物组合物。
• Polylithiation of thioethers: a versatile route for polyanionic synthons
  作者：Miguel Yus、Ana Gutiérrez、Francisco Foubelo

  DOI：10.1016/s0040-4020(01)00374-x

  日期：2001.5

  hydroxy thioether 2. The same methodology was applied to the cyclopropyl phenyl thioether (4), cyclopropyl 1,3-diols 5 E1=tBuCHO, PhCHO, [Me(CH2)4]2CO, (CH2)5CO, (CH2)7CO; E2=tBuCHO, Me2CO, (CH2)5CO} being isolated in moderate yields. The successive treatment of bis(phenylthio)methane (7) with: (a) n-butyllithium at 0°C, (b) a carbonyl compound [E1=tBuCHO, Me2CO, Et2CO, (CH2)5CO] at −40°C, (c) lithium

  苯基乙烯基硫醚（1）与正丁基锂和亲电子体[E 1 = PhCHO，（CH 2）4 CO，（CH 2）5 CO]在-78°C的THF中连续反应，水解后得到预期的亚甲基羟基硫醚（2）。用正丁基锂对2进行质子化，然后进行DTBB催化的锂化反应，并与第二种亲电试剂[E 2 = t BuCHO，PhCHO，Me 2 CO，（CH 2）5 CO]反应，在-78°C下水解相应的亚甲基二醇3。可以从一锅法中从1开始制备相同的二醇，而无需分离羟基硫醚2。将相同的方法应用于环丙基苯基硫醚（4），环丙基1,3-二醇5 E 1 = t BuCHO，PhCHO，[Me（CH 2）4 ] 2 CO，（CH 2）5 CO，（CH 2）7一氧化碳；E 2 = t BuCHO，Me 2 CO，（CH 2）5 CO}以中等收率分离。双（苯硫基）甲烷的连续处理（7）：（a）在0°C时的正丁基锂，（b）在-40°C时的羰基化合物[E
• Carboxylic acid derivative and medicine comprising salt or ester of the same
  申请人：——

  公开号：US20040214888A1

  公开（公告）日：2004-10-28

  The present invention provides novel carboxylic acid derivatives useful as an insulin sensitizer, a salt thereof or a hydrate of them, and a medicament comprising the derivative as the active ingredient. Specifically, it provides a carboxylic acid derivative represented by the following formula: 1 (wherein L represents a single bond, or a C1 to C6 alkylene group, a C2 to C6 alkenylene group or a C2 to C6 alkynylene group, each of which may have one or more substituent groups; M represents a single bond, or a C1 to C6 alkylene group, a C2 to C6 alkenylene group or a C2 to C6 alkynylene group, each of which may have one or more substituent groups; T represents a single bond, or a C1 to C3 alkylene group, a C2 to C3 alkenylene group or a C2 to C3 alkynylene group, each of which may have one or more substituent groups; W represents a carboxyl group; X represents a single bond, an oxygen atom, or a group represented by the various substituent groups including —NR X1 CQ 1 O— (wherein Q 1 represents an oxygen atom or a sulfur atom; R X1 represents a hydrogen atom, a cyano group, a formyl group, or various groups including a C1 to C6 alkyl group and a C1 to C6 hydroxyalkyl group, each of which may have one or more substituent groups), ONR X1 CQ 1 —, —NR X1 CQ 1 —, —CQ 1 NR X1 —, —NR X1a CQ 1 NR X1b —, —Q 2 SO 2 — and —SO 2 Q 2 —; Y represents a 5 to 14-membered aromatic group which may have one or more substituent groups and one or more hetero atoms, or a C3 to C7 alicyclic hydrocarbon group; and the rings Z and U may be the same as or different from each other and each represents a 5 to 14-membered aromatic group which may have 1 to 4 substituent groups and one or more hetero atoms, and the ring may be partially saturated.), a salt thereof, an ester thereof or a hydrate of them.

  本发明提供了一种新型羧酸衍生物，可用作胰岛素增敏剂，其盐或其水合物，以及包含该衍生物作为活性成分的药物。具体而言，本发明提供了一种由以下式子表示的羧酸衍生物：1（其中L表示单键，或C1至C6烷基，C2至C6烯基或C2至C6炔基，每个基团都可以有一个或多个取代基；M表示单键，或C1至C6烷基，C2至C6烯基或C2至C6炔基，每个基团都可以有一个或多个取代基；T表示单键，或C1至C3烷基，C2至C3烯基或C2至C3炔基，每个基团都可以有一个或多个取代基；W表示羧基；X表示单键，氧原子，或由各种取代基表示的基团，包括-NRX1CQ1O-（其中Q1表示氧原子或硫原子；RX1表示氢原子，氰基，甲酰基或各种基团，包括C1至C6烷基和C1至C6羟基烷基，每个基团都可以有一个或多个取代基），ONRX1CQ1-，-NRX1CQ1-，-CQ1NRX1-，-NRX1aCQ1NRX1b-，-Q2SO2-和-SO2Q2-；Y表示一个具有1个或多个取代基和1个或多个杂原子的5至14环芳基，或一个C3至C7脂环烃基；环Z和环U可以相同或不同，每个环表示一个具有1至4个取代基和1个或多个杂原子的5至14环芳基，环可能部分饱和），其盐，酯或其水合物。
• Carboxylic acid derivative and salt thereof
  申请人：——

  公开号：US20040102634A1

  公开（公告）日：2004-05-27

  The present invention provides a novel carboxylic acid compound, a salt thereof or a hydrate of them useful as an insulin sensitizer, and a medicament comprising the compound as an active ingredient. That is, the present invention provides a carboxylic acid compound represented by the following formula, a salt thereof, an ester thereof or a hydrate of them. 1 Wherein R 1 represents a hydrogen atom, hydroxyl group, halogen, carboxyl group, or a C 1-6 alkyl group etc., each of which may have one or more substituents; L represents a single bond, or a C 1-6 alkylene group, a C 2-6 alkenylene group or a C 2-6 alkynylene group, each of which may have one or more substituents; M represents a single bond, or a C 1-6 alkylene group, a C 2-6 alkenylene group or a C 2-6 alkynylene group, each of which may have one or more substituents; T represents a single bond, or a C 1-3 alkylene group, a C 2-3 alkenylene group or a C 2-3 alkynylene group, each of which may have one or more substituents; W represents a carboxyl group; 2 represents a single bond etc.; X represents a single bond, oxygen atom, a group represented by —NR X1 CQ 1 O— (wherein Q 1 represents an oxygen atom or sulfur atom; and R X1 represents a hydrogen atom, formyl group, or a C 1-6 alkyl group etc., each of which may have one or more substituents), —OCQ 1 NR X1 — (wherein Q 1 and R X1 are as defined above), —CQ 1 NR X1 O— (wherein Q 1 and R X1 are as defined above), ONR X1 CQ 1 — (wherein Q 1 and R X1 are as defined above), -Q 2 SO 2 — (wherein Q 2 is an oxygen atom or —NR X10 — (wherein R X10 represents a hydrogen atom, formyl group, or a C 1-6 alkyl group etc., each of which may have one or more substituents)) or —SO 2 Q 2 - (wherein Q 2 is as defined above), (wherein, provided that R X2 and R X3 , and/or R X4 and R X5 may together form a ring, Q 3 and Q 4 are the same as or different from each other and each represents an oxygen atom, (O)S(O) or NR X10 (wherein NR X10 is as defined above)); Y represents a 5- to 14-membered aromatic group etc., which may have one or more substituents and one or more hetero atoms; and the ring Z represents a 5- to 14-membered aromatic group which may have 0 to 4 substituents and one or more hetero atoms, and wherein part of the ring may be saturated.

  本发明提供了一种新型的羧酸化合物、其盐或水合物，作为胰岛素增敏剂，并且提供了一种包含该化合物作为活性成分的药物。即，本发明提供了由以下式表示的羧酸化合物、其盐、酯或水合物。其中，R1表示氢原子、羟基、卤素、羧基或C1-6烷基等，每个都可以有一个或多个取代基；L表示单键，或C1-6烷基、C2-6烯基或C2-6炔基等，每个都可以有一个或多个取代基；M表示单键，或C1-6烷基、C2-6烯基或C2-6炔基等，每个都可以有一个或多个取代基；T表示单键，或C1-3烷基、C2-3烯基或C2-3炔基等，每个都可以有一个或多个取代基；W表示羧基；2表示单键等；X表示单键、氧原子、由—NRX1CQ1O—表示的基团（其中，Q1表示氧原子或硫原子；RX1表示氢原子、甲酰基或C1-6烷基等，每个都可以有一个或多个取代基）、由—OCQ1NRX1—表示的基团（其中，Q1和RX1如上所定义）、由—CQ1NRX1O—表示的基团（其中，Q1和RX1如上所定义）、由ONRX1CQ1—表示的基团（其中，Q1和RX1如上所定义）、由-Q2SO2—表示的基团（其中，Q2是氧原子或—NRX10—（其中，RX10表示氢原子、甲酰基或C1-6烷基等，每个都可以有一个或多个取代基））或由—SO2Q2—表示的基团（其中，Q2如上所定义），（其中，假设RX2和RX3，以及RX4和RX5可以共同形成环，Q3和Q4相同或不同，每个表示氧原子、（O）S（O）或NRX10（其中，NRX10如上所定义））；Y表示5-至14-成员芳香基等，可以有一个或多个取代基和一个或多个杂原子；环Z表示5-至14-成员芳香基，可以有0至4个取代基和一个或多个杂原子，其中环的一部分可以饱和。